KMDA vs. PRTK, FULC, ALT, MIRM, CALT, COLL, PRTA, SAVA, ELVN, and ARQT
Should you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Paratek Pharmaceuticals (PRTK), Fulcrum Therapeutics (FULC), Altimmune (ALT), Mirum Pharmaceuticals (MIRM), Calliditas Therapeutics AB (publ) (CALT), Collegium Pharmaceutical (COLL), Prothena (PRTA), Cassava Sciences (SAVA), Enliven Therapeutics (ELVN), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "medical" sector.
Kamada (NASDAQ:KMDA) and Paratek Pharmaceuticals (NASDAQ:PRTK) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, community ranking, institutional ownership, dividends, profitability and earnings.
Kamada has higher earnings, but lower revenue than Paratek Pharmaceuticals. Paratek Pharmaceuticals is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks.
Kamada has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Paratek Pharmaceuticals has a beta of 1.7, suggesting that its stock price is 70% more volatile than the S&P 500.
Kamada currently has a consensus target price of $11.00, suggesting a potential upside of 108.73%. Paratek Pharmaceuticals has a consensus target price of $2.15, suggesting a potential downside of 3.59%. Given Kamada's stronger consensus rating and higher possible upside, equities analysts clearly believe Kamada is more favorable than Paratek Pharmaceuticals.
In the previous week, Kamada had 2 more articles in the media than Paratek Pharmaceuticals. MarketBeat recorded 2 mentions for Kamada and 0 mentions for Paratek Pharmaceuticals. Kamada's average media sentiment score of 1.07 beat Paratek Pharmaceuticals' score of 0.00 indicating that Kamada is being referred to more favorably in the media.
Kamada has a net margin of 8.33% compared to Paratek Pharmaceuticals' net margin of -35.44%. Kamada's return on equity of 5.50% beat Paratek Pharmaceuticals' return on equity.
Paratek Pharmaceuticals received 123 more outperform votes than Kamada when rated by MarketBeat users. However, 65.13% of users gave Kamada an outperform vote while only 62.39% of users gave Paratek Pharmaceuticals an outperform vote.
20.4% of Kamada shares are held by institutional investors. Comparatively, 53.6% of Paratek Pharmaceuticals shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 8.0% of Paratek Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Kamada beats Paratek Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get Kamada News Delivered to You Automatically
Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KMDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
